In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...